Characterizing the gut microbiota in patients with chronic kidney disease

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Liu ZH. Nephrology in china. Nat Rev Nephrol. 2013;9(9):523–528.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
   PubMed Web of Science ®Google Scholar
• Dai L, Golembiewska E, Lindholm B, et al. End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol. 2017;191:32–43.
   PubMed Web of Science ®Google Scholar
• Iwagami M, Yasunaga H, Matsui H, et al. Impact of end-stage renal disease on hospital outcomes among patients admitted to intensive care units: A retrospective matched-pair cohort study. Nephrology (Carlton). 2017;22(8):617–623.
   PubMed Web of Science ®Google Scholar
• AO K, SK Y, DS Y, et al. The symptoms prevalence, medical interventions, and health care service needs for patients with end-stage renal disease in a renal palliative care program. Am J Hosp Palliat Care. 2016;33(10):952–958.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–358.
   PubMed Web of Science ®Google Scholar
• Cosola C, Rocchetti MT, Cupisti A, et al. Microbiota metabolites: pivotal players of cardiovascular damage in chronic kidney disease. Pharmacol Res. 2018;130:132–142.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Poesen R, Meijers B. The gut-kidney axis. Pediatr Nephrol. 2017;32(11):2005–2014.
   PubMed Web of Science ®Google Scholar
• Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis. 2001;7(2):136–145.
   PubMed Web of Science ®Google Scholar
• Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115–1118.
   PubMed Web of Science ®Google Scholar
• Umesaki Y, Setoyama H. Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect. 2000;2(11):1343–1351.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Onal EM, Afsar B, et al. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. Int Urol Nephrol. 2018;50(8):1453–1466.
   PubMed Web of Science ®Google Scholar
• Meijers B, Jouret F, Evenepoel P. Linking gut microbiota to cardiovascular disease and hypertension: lessons from chronic kidney disease. Pharmacol Res. 2018;133:101–107.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21(6):587–592.
   PubMed Web of Science ®Google Scholar
• Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. J Nutr. 2017;147(7):1468S–1475S.
   PubMed Web of Science ®Google Scholar
• Yoshifuji A, Wakino S, Irie J, et al. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant. 2016;31(3):401–412.
   PubMed Web of Science ®Google Scholar
• Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
   PubMed Web of Science ®Google Scholar
• Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331–1340.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–315.
   PubMed Web of Science ®Google Scholar
• Kieffer DA, Piccolo BD, Vaziri ND, et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol. 2016;310(9):F857–871.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Liu SM, Lau WL, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One. 2014;9(12):e114881.
   PubMed Web of Science ®Google Scholar
• Laffin MR, Tayebi Khosroshahi H, Park H, et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodial Int. 2019;23(3):343–347.
   PubMed Web of Science ®Google Scholar
• Tayebi Khosroshahi H, Vaziri ND, Abedi B, et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodial Int. 2018;22(4):492–500.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100.
   PubMed Web of Science ®Google Scholar
• Kong X, Ma Y, Chen J, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28(3):641–651.
   PubMed Web of Science ®Google Scholar
• Wang Q, Garrity GM, Tiedje JM, et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261–5267.
   PubMed Web of Science ®Google Scholar
• Aßhauer KP, Wemheuer B, Daniel R, et al. Tax4Fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics. 2015;31(17):2882–2884.
   PubMed Web of Science ®Google Scholar
• Chung S, Barnes JL, Astroth KS. Gastrointestinal microbiota in patients with chronic kidney disease: a systematic review. Adv Nutr. 2019;10(5):888–901.
   PubMed Web of Science ®Google Scholar
• Sampaio-Maia B, Simões-Silva L, Pestana M, et al. The role of the gut microbiome on chronic kidney disease. Adv Appl Microbiol. 2016;96:65–94.
   PubMed Web of Science ®Google Scholar
• Jiang S, Xie S, Lv D, et al. A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie Van Leeuwenhoek. 2016;109(10):1389–1396.
   PubMed Web of Science ®Google Scholar
• Li F, Wang M, Wang J, et al. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease. Front Cell Infect Microbiol. 2019;9:206.
   PubMed Web of Science ®Google Scholar
• Barrios C, Beaumont M, Pallister T, et al. Gut-microbiota-metabolite axis in early renal function decline. PLoS One. 2015;10(8):e0134311.
   PubMed Web of Science ®Google Scholar
• Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178–184.
   PubMed Web of Science ®Google Scholar
• Jiang S, Xie S, Lv D, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7(1):2870.
   PubMed Web of Science ®Google Scholar
• Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, et al. The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother. 2017;93:412–419.
   PubMed Web of Science ®Google Scholar
• Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496–503.
   PubMed Web of Science ®Google Scholar
• Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2(3):204.
   PubMed Web of Science ®Google Scholar
• Xu KY, Xia GH, Lu JQ, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445.
   PubMed Web of Science ®Google Scholar
• Wang F, Jiang H, Shi K, et al. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton). 2012;17(8):733–738.
   PubMed Web of Science ®Google Scholar
• Strid H, Simrén M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67(3):129–137.
   PubMed Web of Science ®Google Scholar
• Chassaing B, Koren O, Carvalho FA, et al. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut. 2014;63(7):1069–1080.
   PubMed Web of Science ®Google Scholar
• Pan W, Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol. 2018;50(2):289–299.
   PubMed Web of Science ®Google Scholar
• Flannigan KL, Taylor MR, Pereira SK, et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. J Heart Lung Transplant. 2018;37(9):1047–1059.
   PubMed Web of Science ®Google Scholar
• Tesh VL, O’Brien AD. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Microbiol. 1991;5(8):1817–1822.
   PubMed Web of Science ®Google Scholar
• Song YF, Pei LX, Chen L, et al. Electroacupuncture relieves irritable bowel syndrome by regulating IL-18 and gut microbial dysbiosis in a trinitrobenzene sulfonic acid-induced post-inflammatory animal model. Am J Chin Med. 2020;48(1):77–90.
   PubMed Web of Science ®Google Scholar
• Dong Y, Cheng H, Liu Y, et al. Red yeast rice ameliorates high-fat diet-induced atherosclerosis in Apoe-/- mice in association with improved inflammation and altered gut microbiota composition. Food Funct. 2019;10(7):3880–3889.
   PubMed Web of Science ®Google Scholar
• Huang S, Mao J, Zhou L, et al. The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients. Scand J Immunol. 2019;90(3):e12799.
   PubMed Web of Science ®Google Scholar
• He Z, Shao T, Li H, et al. Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus. Gut Pathog. 2016;8:64.
   PubMed Web of Science ®Google Scholar
• Caspi R, Billington R, Ferrer L, et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2016;44(D1):D471–480.
   PubMed Web of Science ®Google Scholar
• Pan X, Xue F, Nan X, et al. Illumina sequencing approach to characterize thiamine metabolism related bacteria and the impacts of thiamine supplementation on ruminal microbiota in dairy cows fed high-grain diets. Front Microbiol. 2017;8:1818.
   PubMed Web of Science ®Google Scholar
• Kunisawa J. Metabolic changes during B cell differentiation for the production of intestinal IgA antibody. Cell Mol Life Sci. 2017;74(8):1503–1509.
   PubMed Web of Science ®Google Scholar
• Kunisawa J, Sugiura Y, Wake T, et al. Mode of bioenergetic metabolism during B cell differentiation in the intestine determines the distinct requirement for vitamin B1. Cell Rep. 2015;13(1):122–131.
   PubMed Web of Science ®Google Scholar
• Hung SC, Hung SH, Tarng DC, et al. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2001;38(5):941–947.
   PubMed Web of Science ®Google Scholar
• Saka Y, Naruse T, Kato A, et al. Thiamine status in end-stage chronic kidney disease patients: a single-center study. Int Urol Nephrol. 2018;50(10):1913–1918.
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455.
   PubMed Web of Science ®Google Scholar
• Schulthess J, Pandey S, Capitani M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity. 2019;50(2):432–445.e7.
   PubMed Web of Science ®Google Scholar
• Genoni A, Christophersen CT, Lo J, et al. Long-term Paleolithic diet is associated with lower resistant starch intake, different gut microbiota composition and increased serum TMAO concentrations. Eur J Nutr. 2019:1–14.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen DQ, Liu JR, et al. Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Exp Mol Med. 2019;51(3):1–18.
   Web of Science ®Google Scholar
• Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7(1):91.
   PubMed Web of Science ®Google Scholar
• Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237.
   PubMed Web of Science ®Google Scholar
• Lun H, Yang W, Zhao S, et al. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. Microbiologyopen. 2019;8(4):e00678.
   PubMed Web of Science ®Google Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.
   PubMed Web of Science ®Google Scholar
• Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014–1023.
   PubMed Web of Science ®Google Scholar
• Zhou D, Liu Y. Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12(2):68–70.
   PubMed Web of Science ®Google Scholar
• Bagnasco S, Balaban R, Fales HM, et al. Predominant osmotically active organic solutes in rat and rabbit renal medullas. J Biol Chem. 1986;261(13):5872–5877.
   PubMed Web of Science ®Google Scholar
• Burg MB. Renal osmoregulatory transport of compatible organic osmolytes. Curr Opin Nephrol Hypertens. 1997;6(5):430–433.
   PubMed Web of Science ®Google Scholar
• Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018;362(6416):776–780.
   PubMed Web of Science ®Google Scholar